Literature DB >> 15760085

Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration.

Vanna Sanna1, Nathalie Kirschvink, Pascal Gustin, Elisabetta Gavini, Isabelle Roland, Luc Delattre, Brigitte Evrard.   

Abstract

The purpose of this research was to investigate the effects of processing conditions on the characteristics of solid lipid microparticles (SLM) with a potential application as carriers for pulmonary administration. Compritol (5.0% wt/wt) SLM dispersions were prepared by rotor-stator homogenization, at different surfactant concentrations and emulsification times. The SLM were characterized, in terms of morphology and size, after lyophilization and sterilization by autoclaving process. In vivo assessment was carried out in rats by intratracheal instillation of either placebo or SLM dispersion, and by bronchoalveolar lavage for cytological analysis. Mean particle size of 4 to 5 microm was achieved using 0.3% and 0.4% (wt/wt) of emulsifier (Poloxamer 188) and emulsification times of 2 and 5 minutes. The particles showed spherical shape and smooth surface. The morphology of microparticles, the size, and the size distribution were not substantially modified after lyophilization and sterilization. Total cell counts showed no significant differences between placebo and SLM 0.5% or 2.5% groups. Regarding cytology, percentage of polymorphonuclear neutrophils and macrophages did not significantly differ between groups. These results suggest that a single intratracheal administration of the SLMs does not induce a significant inflammatory airway response in rats and that the SLMs might be a potential carrier for encapsulated drug via the pulmonary route.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15760085      PMCID: PMC2750462          DOI: 10.1208/pt050227

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  23 in total

1.  Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles.

Authors:  A Lippacher; R H Müller; K Mäder
Journal:  Int J Pharm       Date:  2001-02-19       Impact factor: 5.875

Review 2.  Solid lipid nanoparticles: production, characterization and applications.

Authors:  W Mehnert; K Mäder
Journal:  Adv Drug Deliv Rev       Date:  2001-04-25       Impact factor: 15.470

3.  The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.

Authors:  H Larhrib; X M Zeng; G P Martin; C Marriott; J Pritchard
Journal:  Int J Pharm       Date:  1999-11-25       Impact factor: 5.875

4.  Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant.

Authors:  R H Müller; D Rühl; S Runge; K Schulze-Forster; W Mehnert
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

5.  Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin.

Authors:  Roberta Cavalli; Alessandro Bargoni; Valerio Podio; Elisabetta Muntoni; Gian Paolo Zara; Maria Rosa Gasco
Journal:  J Pharm Sci       Date:  2003-05       Impact factor: 3.534

6.  Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism.

Authors:  A zur Mühlen; C Schwarz; W Mehnert
Journal:  Eur J Pharm Biopharm       Date:  1998-03       Impact factor: 5.571

7.  Liposomal budesonide for dry powder inhaler: preparation and stabilization.

Authors:  M R Joshi; A Misra
Journal:  AAPS PharmSciTech       Date:  2001-11-30       Impact factor: 3.246

8.  Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells.

Authors:  Corinne Erni; Catherine Suard; Sergio Freitas; Donatus Dreher; Hans P Merkle; Elke Walter
Journal:  Biomaterials       Date:  2002-12       Impact factor: 12.479

9.  Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization.

Authors:  F Q Hu; H Yuan; H H Zhang; M Fang
Journal:  Int J Pharm       Date:  2002-06-04       Impact factor: 5.875

10.  Evaluation of polar lipid-hydrophilic polymer microparticles.

Authors:  Marja Savolainen; Jenny Herder; Cynthia Khoo; Karin Lövqvist; Carina Dahlqvist; Håkan Glad; Anne Mari Juppo
Journal:  Int J Pharm       Date:  2003-08-27       Impact factor: 5.875

View more
  13 in total

1.  Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.

Authors:  Sonali R Naikwade; Amrita N Bajaj; Prashant Gurav; Madhumanjiri M Gatne; Pritam Singh Soni
Journal:  AAPS PharmSciTech       Date:  2009-08-01       Impact factor: 3.246

2.  Solid lipid budesonide microparticles for controlled release inhalation therapy.

Authors:  Matteo Mezzena; Santo Scalia; Paul M Young; Daniela Traini
Journal:  AAPS J       Date:  2009-11-12       Impact factor: 4.009

3.  Insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies.

Authors:  Reshma D'Souza; Srinivas Mutalik; Madhavacharya Venkatesh; Sudha Vidyasagar; Nayanabhirama Udupa
Journal:  AAPS PharmSciTech       Date:  2005-09-30       Impact factor: 3.246

4.  Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.

Authors:  Ram R Patlolla; Mahavir Chougule; Apurva R Patel; Tanise Jackson; Prasad N V Tata; Mandip Singh
Journal:  J Control Release       Date:  2010-02-11       Impact factor: 9.776

5.  Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery.

Authors:  Dhrumil Upadhyay; Santo Scalia; Robert Vogel; Nial Wheate; Rania O Salama; Paul M Young; Daniela Traini; Wojciech Chrzanowski
Journal:  Pharm Res       Date:  2012-05-15       Impact factor: 4.200

6.  Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks.

Authors:  Hanan M El-Laithy; Amal Youssef; Shereen S El-Husseney; Nesrine S El Sayed; Ahmed Maher
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis.

Authors:  Jagadevappa S Patil; V Kusum Devi; Kshama Devi; S Sarasija
Journal:  Lung India       Date:  2015 Jul-Aug

8.  Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity.

Authors:  Arpana A Patil-Gadhe; Abhay Y Kyadarkunte; Michael Pereira; Gauri Jejurikar; Milind S Patole; Arun Risbud; Varsha B Pokharkar
Journal:  Toxicol Int       Date:  2014 Sep-Dec

9.  Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD).

Authors:  Monika Yadav; Nicola Schiavone; Ana Guzman-Aranguez; Fabrizio Giansanti; Laura Papucci; Maria J Perez de Lara; Mandeep Singh; Indu Pal Kaur
Journal:  Drug Deliv Transl Res       Date:  2020-08       Impact factor: 4.617

10.  Formulation of inhalable lipid-based salbutamol sulfate microparticles by spray drying technique.

Authors:  Zahra Daman; Kambiz Gilani; Abdolhossein Rouholamini Najafabadi; Hamid Reza Eftekhari; Mohammad Ali Barghi
Journal:  Daru       Date:  2014-06-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.